Shots:Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC)Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemabThe interview gives an understanding of Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…
